Guggenheim analyst Brad Canino initiated coverage of Janux Therapeutics (JANX) with a Buy rating and $72 price target The firm believes the company can create significant shareholder value given its “best-in-category” JANX007 prostate-specific antigen responses in metastatic castration-resistant prostate cancer. The analyst views Janux as an attractive pure-play investment for T cell engagers in solid tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics initiated with a Buy at Guggenheim
- Piper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potential
- Janux Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations
- Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials